American Association for Cancer Research
Browse
00085472can060025-sup-can_7-1-06_samanta.pdf (184.28 kB)

Supplementary Figures S1-S6 & Legends from Janus Kinase 2: A Critical Target in Chronic Myelogenous Leukemia

Download (184.28 kB)
journal contribution
posted on 2023-03-30, 16:48 authored by Ajoy K. Samanta, Hui Lin, Tong Sun, Hagop Kantarjian, Ralph B. Arlinghaus
Supplementary Figures S1-S6 & Legends from Janus Kinase 2: A Critical Target in Chronic Myelogenous Leukemia

History

ARTICLE ABSTRACT

The Bcr-Abl tyrosine kinase is the causative factor in most chronic myelogenous leukemia (CML) patients. We have shown that Bcr-Abl is associated with a cluster of signaling proteins, including Janus kinase (Jak) 2, growth factor receptor binding protein 2–associated binder (Gab) 2, Akt, and glycogen synthase kinase (GSK)-3β. Treatment of CML cell lines and mouse Bcr-Abl+ 32D cells with either Jak2 short interfering RNA or Jak2 kinase inhibitor AG490 inhibited pTyr Gab2 and pSer Akt formation, inhibited the activation of nuclear factor-κB, and caused the activation of GSK-3β, leading to the reduction of c-Myc. Importantly, BaF3 cells expressing T315I and E255K imatinib-resistant mutants of Bcr-Abl underwent apoptosis on exposure to AG490 yet were resistant to imatinib. Similar to wild-type Bcr-Abl+ cells, inhibition of Jak2 by Ag490 treatment resulted in decrease of pSer Akt and c-Myc in imatinib-resistant cells. These results identify Jak2 as a potentially important therapeutic target for CML. (Cancer Res 2006; 66(13): 6468-72)

Usage metrics

    Cancer Research

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC